Expressions of Her-2, EGFR, PS-2 and ER in breast cancer and their clinical implications.
- Author:
Lei XU
1
;
Zhong-hong BAI
;
Ruan-cheng XU
;
Hui YAN
;
Fang-ju WANG
;
Rong-cheng LUO
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Biomarkers, Tumor; biosynthesis; Breast Neoplasms; metabolism; pathology; Carcinoma, Ductal, Breast; metabolism; pathology; Female; Humans; Immunohistochemistry; Middle Aged; Presenilin-2; biosynthesis; Prognosis; Receptor, Epidermal Growth Factor; biosynthesis; Receptor, ErbB-2; biosynthesis; Receptors, Estrogen; biosynthesis
- From: Journal of Southern Medical University 2006;26(2):231-233
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo detect the expressions of human epidermal growth factor receptor 2 (Her-2), epidermal growth factor receptor (EGFR), presenilin 2 (PS-2) and estrogen receptor (ER) in breast cancer and discuss their clinical implications.
METHODSThe expressions of Her-2, EGFR, PS-2 and ER were measured immunohistochemically in 108 patients with breast cancer.
RESULTSThe positive expression rates of Her-2, EGFR, PS-2 and ER were 37.0%, 40.7%, 57.4% and 53.7% respectively in the breast cancer patients. The expression of Her-2 was not correlated with EGFR, but inversely correlated with PS-2 and ER. The expressions of Her-2 and EGFR, PS-2, ER were correlated with the histological grades (P<0.05), and Her-2, EGFR and ER expressions with lymph node metastasis (P<0.05). The expressions of Her-2, EGFR, PS-2 and ER did not correlate to the pathological types, patient's age and tumor size (P>0.05).
CONCLUSIONExpressions of Her-2 and EGFR often suggests an unfavorable prognosis while expressions of PS-2 and ER suggest a more favorable one. Expressions of Her-2, EGFR, PS-2 and ER are useful prognostic factors in breast cancer patients.